各种介入治疗肝癌方法临床评价

doi:10.3969/j.issn.1672-5069.2015.02.003

实用肝脏病杂志 ›› 2015, Vol. 18 ›› Issue (3): 230-232.doi: 10.3969/j.issn.1672-5069.2015.02.003

各种介入治疗肝癌方法临床评价

杨晋辉, 唐映梅

650033 昆明市昆明医科大学第二附属医院肝胆胰内科/云南省肝病研究中心

收稿日期:2015-03-19 出版日期:2015-05-10 发布日期:2016-02-19
通讯作者: 唐映梅,E-mail：tangyingmei@163.com
作者简介:杨晋辉,男,52岁,教授,主任医师,硕士生导师

Evaluation of interventional therapy for patients with hepatocellular carcinoma

Yang Jinhui, Tang Yingmei

Department of Hepatobiliary and Pancreatic Medicine, Center for Liver Diseases, Second Affiliated Hospital, Kunming Medical University, Kunming 650033

Received:2015-03-19 Online:2015-05-10 Published:2016-02-19
Contact: Tang Yingmei, E-mail:tangyingmei@163.com

摘要/Abstract

关键词: 肝癌, 介入治疗, 临床评价

Key words: Hepatocellular carcinoma, Interventional therapy, Clinical evaluation

杨晋辉, 唐映梅. 各种介入治疗肝癌方法临床评价[J]. 实用肝脏病杂志, 2015, 18(3): 230-232.

Yang Jinhui, Tang Yingmei. Evaluation of interventional therapy for patients with hepatocellular carcinoma[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(3): 230-232.

[1] Lencioni R,Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology,2012,262（1）:43-58.
[2] Lewandowski RJ,Geschwind JF,Liapi E,et al. Transcatheter intraarterial therapies:rationale and overview. Radiology,2011,259（3）:641-657.
[3] Georgiades C,Geschwind JF,Harrison N,et al. Lack of response after initial chemoembolization for hepatocellular carcinoma:does it predict failure of subsequent treatment. Radiology,2012,265（1）:115-123.
[4] Luo J,Guo RP,Lai EC,et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis:a prospective comparative study. Ann Surg Oncol,2011,18（2）:413-420.
[5] 王建华. 肝癌综合介入治疗的进展. 中华介入放射学电子杂志,2013,1（1）:61-64.
[6] Prajapati HJ,Xing M,Spivey JR,et al. Survival,efficacy,and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC. AJR,2014,203（6）:W706-W714.
[7] Yu SC,Hui JW,Hui EP,et al. Unresectable hepatocellular carcinoma:randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization.Radiology,2014,270（2）:607-620.
[8] 黄兢姚,杨维竹,江娜,等. 经皮门静脉栓塞治疗肝癌的临床应用. 介入放射学杂志,2006,15（11）:664-666.
[9] 曹玮,万教,张洪新,等. 肝动脉、门静脉双介入治疗对肝癌患者微循环状态的影响. 现代肿瘤医学,2008,16（11）:1958-1959.
[10] Lee DH,Lee JM,Lee JY,et al. Radiofrequency ablation of hepatocellular carcinoma as first-line treatment:long-term results and prognostic factors in 162 patients with cirrhosis. Radiology,2014,270（3）:900-909.
[11] Huang G,Chen X,Lau WY,et al. Quality of life after surgical resection compared with radiofrequency ablation for small hepatocellular carcinomas.Br J Surg,2014,101（8）:1006-1015.
[12] Kariyama K,Nouso K,Wakuta A,et al. Percutaneous radiofrequency ablation for treatment of hepatocellular carcinoma in the caudate lobe. AJR,2011,197（4）:W571-W575.
[13] Xu HX,Wang Y,Lu MD,et al. Percutaneous ultrasound-guided thermal ablation for intrahepatic cholangiocarcinoma. Br J Radiol, 2012,85（1016）:1078-1084.
[14] Pereira PL,Trübenbach J,Schenk M,et al. Radiofrequency ablation:in vivo comparison of four commercially available devices in pig livers. Radiology,2004,232（2）:482-490.
[15] Curley SA,Izzo F,Ellis LM,et al. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg,2000,232:381-391.
[16] Wood TF,Rose DM,Chung M,et al. Radiofrequency ablation of 231 unresectable hepatic tumors:indications,limitations and complications. Ann Surg Oncol,2000,7（8）:593-600.
[17] 彭晓君,王春平,任永强,等. 经皮射频毁损治疗96例肝癌疗效分析. 中国现代医学杂志,2003,13（4）:39-42.
[18] Takaki H,Yamakado K,Nakatsuka A,et al. Frequency of and risk factors for complications after liver radiofrequency ablation under CT fluoroscopic guidance in 1500 sessions:single-center experience. AJR,2013,200（3）:658-664.
[19] Ishizaka H,Awata S,Arai H,et al. CT-guided radiofrequency liver tumour ablation:use of a two-step coaxial system with a fine guide needle wire unit for high-risk cases. Br J Radiol,2010,83（996）:1077-1079.
[20] Goldberg SN. Science to practice:why debate the role of Dbait for improving tumor ablation. Radiology,2014,270（3）:635-637.
[21] Mahnken AH,Pereira PL,de Baère T. Interventional oncologic approaches to liver metastases. Radiology,2013,266（2）:407-430.
[22] 赵新建,岳丽娟.肝癌介入治疗的研究现状. 农垦医学,2006,28（5）:380-384.

各种介入治疗肝癌方法临床评价

Evaluation of interventional therapy for patients with hepatocellular carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	鲍应军, 任伟新. 门静脉血栓介入治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(6): 768-769.
[2]	邢昊, 韩骏, 杨田. 应用血清PIVKA-II诊断肝细胞癌研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 934-937.
[3]	刘杏, 赵树立, 张殿隆. 七氟烷吸入时机对肝脏部分切除术患者肝脏缺血再灌注损伤的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 728-731.
[4]	裴颖, 黄峰, 殷宏振, 郭化磊. 去甲斑蝥酸钠对肝癌异位移植瘤小鼠肠道微生态的影响初探*[J]. 实用肝脏病杂志, 2019, 22(4): 486-489.
[5]	戴青云, 王润东, 荚卫东. 术前预后营养指数评估肝细胞癌患者肝切除术后早期肿瘤复发价值探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 561-564.
[6]	崔发强, 李涛, 王铮, 陈青. 原发性肝癌患者外周血KRAS基因水平及其对西妥昔单克隆抗体治疗疗效的影响[J]. 实用肝脏病杂志, 2019, 22(4): 565-568.
[7]	赵晓光, 史玉洁. 应用还原型谷胱甘肽预防处理接受TACE治疗的中晚期原发性肝癌患者对肝功能的影响[J]. 实用肝脏病杂志, 2019, 22(3): 425-428.
[8]	李克田,沈明格,王凤荣,胡春荣,曹玉杰,芦鹏. 血糖水平对原发性肝癌患者¹⁸F-FDG摄取和PET/CT检查图像质量的影响研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 256-259.
[9]	张帮健,魏寿存,杨小燕. 右美托咪啶联合丙泊酚麻醉对肝癌切除术患者围手术期血清细胞因子和术后苏醒质量的影响 ^*[J]. 实用肝脏病杂志, 2019, 22(2): 264-267.
[10]	李芳, 邹桂舟, 叶珺, 郜玉峰. 不同HBV感染转归人群外周血PD-1拷贝数分布研究^*[J]. 实用肝脏病杂志, 2019, 22(1): 37-40.
[11]	王翠晓, 高静. 血清高尔基蛋白73、甲胎蛋白异质体3、甲胎蛋白和α-L-岩藻糖苷酶水平诊断原发性肝癌的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(1): 113-116.
[12]	陈向, 汪宝林, 吴琛, 唐劲草, 张弛, 褚朝顺. 动脉灌注化疗栓塞联合放射粒子植入治疗原发性肝癌患者疗效及其对肝组织TRF1和TRF2表达的影响^*[J]. 实用肝脏病杂志, 2019, 22(1): 121-124.
[13]	闫书鸣, 王建国, 李泽信, 游焜, 王亮, 郭鹏威. 门冬氨酸鸟氨酸治疗肝癌切除术患者对肝脏缺血再灌注损伤的保护作用研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 932-935.
[14]	汪华, 赵亚宁. 索拉菲尼治疗进展期原发性肝癌患者有效性及安全性研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 936-939.
[15]	嵇小琴综述, 龚健审校. 老年CHC临床特点及抗病毒治疗策略研究进展[J]. 实用肝脏病杂志, 2018, 21(6): 995-998.